<DOC>
	<DOCNO>NCT01366547</DOCNO>
	<brief_summary>Dolutegravir ( DTG , GSK1349572 ) next-generation integrase inhibitor ( INI ) currently phase 3 clinical trial human immunodeficiency virus ( HIV ) . Fixed-dose combination ( FDCs ) greatly simplify treatment patient HIV . While Atripla ( FDC tenofovir ( TDF ) , emtricitabine ( FTC ) efavirenz ( EFV ) ) become preferred first line regimen due large part convenient presentation full treatment regimen single product , option need . A fixed-dose combination DTG/abacavir ( ABC ) /lamivudine ( 3TC ) one opportunity . This single-center , randomize , open-label , 3-period crossover study healthy adult subject evaluate single-dose relative bioavailability two experimental oral DTG 50 mg/ABC 600 mg/3TC 300 mg FDC tablet formulation compare co-administration separate tablet formulation ( DTG 50 mg tablet EPZICOM ) , dose administer fasted state . Approximately 18 subject enrol randomize one 6 different treatment sequence . There screen visit within 30 day prior first dose study drug follow visit within 7-14 day last dose . There 7 day washout dos treatment period . The following PK parameter DTG , ABC 3TC measure : area concentration curve time zero ( pre-dose ) extrapolate infinite time ( AUC ( 0-infinity ) ) , Area concentration-time curve time zero ( pre-dose ) time last quantifiable concentration ( AUC ( 0-t ) ) , maximum observed concentration ( Cmax ) , lag time observation drug concentration ( tlag ) , time occurrence Cmax ( tmax ) , terminal phase half-life ( t½ ) , apparent clearance follow oral dosing ( CL/F ) apparent terminal phase volume distribution ( Vz/F ) .</brief_summary>
	<brief_title>Relative Bioavailability Study Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets</brief_title>
	<detailed_description>Official Title - Randomized , Open-Label , Single Dose , 3 Period , Crossover Evaluation Relative Bioavailability Two Experimental Fixed-Dose Combination Tablet Formulations Dolutegravir 50 mg/Abacavir 600 mg/Lamivudine 300 mg Compared Co administer Dolutegravir 50 mg EPZICOM™ ( Abacavir 600 mg/Lamivudine 300 mg ) Tablets Healthy Adult Subjects . ViiV Healthcare new sponsor study , GlaxoSmithKline process update system reflect change sponsorship</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<mesh_term>Integrase Inhibitors</mesh_term>
	<criteria>Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . Male female 18 65 year age inclusive , time signing informed consent . A female subject eligible participate : Nonchildbearing potential childbearing potential agrees use one contraception method list protocol followup visit . Male subject female partner childbearing potential must agree use one contraception method list protocol 84 day last dose study drug . Body weight great 50 kg male great 45 kg female BMI within range 18.5 31.0 kg/m2 ( inclusive ) . ALT , alkaline phosphatase bilirubin le 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . A negative HLAB*5701 allele screen assessment Capable give write informed consent , include compliance requirement restriction list consent form . The subject positive prestudy drug/alcohol screen . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids benzodiazepine . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . History sensitivity study medication , component thereof , history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . If heparin use PK sample , subject history sensitivity heparin heparininduced thrombocytopenia enrol . History regular alcohol consumption within 6 month study define : An average weekly intake &gt; 14 drinks/week men &gt; 7 drinks/week woman . 7 . Consumption red wine , seville orange , grapefruit grapefruit juice 7 day prior first dose study medication . Pregnant female determine positive serum urine human chorionic gonadotrophin ( hCG ) test screen prior dosing . Lactating female . Unwillingness inability follow procedure outline protocol . Subjects preexist condition interfere normal gastrointestinal anatomy motility , hepatic and/or renal function , could interfere absorption , metabolism , and/or excretion study drug . Subjects history cholecystectomy , peptic ulceration , inflammatory bowel disease pancreatitis exclude . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . A positive test HIV antibody . History Gilbert 's disease . Where participation study would result donation blood blood product excess 500 mL within 56 day period . The subject 's systolic blood pressure outside range 90140mmHg , diastolic blood pressure outside range 4590mmHg heart rate outside range 50100bpm female subject 45100 bpm male subject . Exclusion criterion screen ECG outside protocol limit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Bioavailability</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Dolutegravir</keyword>
	<keyword>integrase</keyword>
	<keyword>Abacavir</keyword>
</DOC>